<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03449628</url>
  </required_header>
  <id_info>
    <org_study_id>PSC-DS PROBE2-IBS/17</org_study_id>
    <nct_id>NCT03449628</nct_id>
  </id_info>
  <brief_title>L. Casei DG® in Patients With Irritable Bowel Syndrome.</brief_title>
  <acronym>PROBE2</acronym>
  <official_title>L. Casei DG® (Lactobacillus Paracasei CNCMI1572) in the Treatment of Patients With Irritable Bowel Syndrome: a Multicenter, Randomized, Double-Blind, Parallel-Group, Placebo Controlled Study.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>SOFAR S.p.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>1Med</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>SOFAR S.p.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effect of L. casei DG® (Lactobacillus paracasei CNCMI1572; Enterolactis® plus)
      on abdominal symptoms and gut microbiota metabolism/composition in non constipated patients
      with IBS (Irritable Bowel Syndrome). Patients will be randomized to receive L. casei DG®
      capsules, b.i.d. for 12 weeks the a 4 weeks Follow Up period will follow.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 6, 2017</start_date>
  <completion_date type="Anticipated">June 10, 2019</completion_date>
  <primary_completion_date type="Anticipated">May 10, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of patients who have a response in pain</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients who record on ≥ 50% of the days a reduction of ≥ 30% from their average baseline score for their worst abdominal pain.The standard 11-point numeric rating scale (from 0=none to 10=worst possible pain) will be used to measure abdominal pain.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of patients who have a response in stool consistencies</measure>
    <time_frame>12 weeks</time_frame>
    <description>Patients who record a stool-consistency score &lt; 5 in the same days in which they record a reduction of ≥ 30% from their average baseline score for their worst abdominal pain .For abnormal defecation, stool frequency and form will be measured using the Bristol Stool Form Scale (BSFS).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluation of Pain relief</measure>
    <time_frame>16 weeks</time_frame>
    <description>reduction of ≥ 30% from baseline in the score for the worst abdominal pain on ≥ 50% of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of global symptom score</measure>
    <time_frame>16 weeks</time_frame>
    <description>Improvement in the global symptom score: a score of 0 or 1, or an improvement ≥ 2 over the baseline score, on ≥ 50% of days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relief of IBS symptoms</measure>
    <time_frame>16 weeks</time_frame>
    <description>Adequate relief of IBS symptoms on ≥ 50% of the past weeks (a response of &quot;yes&quot; on ≥50% of the weeks to the following question: &quot;Over the past week, have you had adequate relief of your IBS symptoms?)&quot;</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IBS-SSS score questionnaire (Severity Scoring System )</measure>
    <time_frame>16 weeks</time_frame>
    <description>To assess the severity of symptoms related to Irritable Bowel Syndrome, assessed at baseline and at the end of treatment after 12 weeks (it is considered clinically significant a score reduction of at least 50 points). The questionnaire is composed by five questions wich generate a maximum score of 100 each using prompted visual analogue scales, leading to a total possible score of 500.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Improvement in stool consistency</measure>
    <time_frame>16 weeks</time_frame>
    <description>stool consistency score ≤ 5 assessed with BSFS (Bristol Stool Form Scale) BSFS evaluates stool form and consistency (score from 1=dry stool to 7=liquid stoo. The ideal stool is generally 3 or 4)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Satisfaction with treatment</measure>
    <time_frame>16 weeks</time_frame>
    <description>Overall satisfaction with treatment assessed by VAS scale (Visual Analogue Scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>16 weeks</time_frame>
    <description>Quality of life assessment by validated Short-Form 12 Items Health Survey (SF-12) on a scale of 0 to 100</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intake of rescue medication</measure>
    <time_frame>16 weeks</time_frame>
    <description>type and frequencies of rescue medication</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>gut microbiota composition</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluation of changes in the gut microbiota composition and the relative abundance of bacterial OTUs (Operational Taxonomic Unit).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Short Chain Fatty Acids (SCFA)</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluation of Short Chain Fatty Acids levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Free Aminoacids</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluation of Free aminoacids levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Biogenic Amines</measure>
    <time_frame>16 weeks</time_frame>
    <description>Evaluation of biogenic amines levels in fecal samples</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut permeability for zonulin</measure>
    <time_frame>16 weeks</time_frame>
    <description>evaluation of serum levels of zonulin</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut permeability for citrulline</measure>
    <time_frame>16 weeks</time_frame>
    <description>evaluation of serum levels of citrulline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gut permeability for PV-1 (Plasmalemma vesicle-associated) protein</measure>
    <time_frame>16 weeks</time_frame>
    <description>evaluation of serum levels of PV-1 (Plasmalemma vesicle-associated) protein</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>L. casei DG® strain in the feces</measure>
    <time_frame>16 weeks</time_frame>
    <description>the recovery of L. casei DG® strain in the feces</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>IBS - Irritable Bowel Syndrome</condition>
  <arm_group>
    <arm_group_label>L. casei DG®</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Interventions: Lactobacillus paracasei CNCMI1572 (At least 24 billion live cells per capsule)
1 capsule, b.i.d. for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Interventions : capsules for oral use, indistinguishable from active product.
1 capsule, b.i.d. for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>L.casei DG</intervention_name>
    <description>(At least 24 billion live cells per capsule)
1 capsule, b.i.d. for 12 weeks</description>
    <arm_group_label>L. casei DG®</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>PLACEBO</intervention_name>
    <description>1 capsule, b.i.d. for 12 weeks</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Age &gt; 18 years and ≤ 65 years

          -  A positive diagnosis of non constipated IBS (i.e., IBS-D and IBS-M, both males and
             females), according to Rome IV criteria.

          -  Negative outcome of barium enema X-ray or colonoscopy within the previous two years

          -  Negative relevant additional screening or consultation whenever appropriate

          -  Ability to conform to the study protocol.

        Exclusion Criteria:

          -  Patients with IBS-C or IBS-U according to Rome IV criteria

          -  Presence of any relevant organic, systemic or metabolic disease (particularly
             significant history of cardiac, renal, neurological, psychiatric, oncology,
             endocrinology, metabolic or hepatic disease), or abnormal laboratory values that will
             be deemed clinically significant on the basis of predefined values, (i.e..liver or
             kidney functional levels 2-times greater than the upper reference values)

          -  Ascertained intestinal organic diseases, including celiac disease, food allergies or
             inflammatory bowel diseases (Crohn's disease, ulcerative colitis, diverticular
             disease, infectious colitis, ischemic colitis, microscopic colitis).

          -  Previous major abdominal surgery.

          -  Active malignancy of any type, or history of a malignancy (patients with a history of
             other malignancies that have been surgically removed and who have no evidence of
             recurrence for at least five years before study enrolment are also acceptable).

          -  Untreated food intolerance such as ascertained or suspected lactose intolerance, as
             defined by anamnestic evaluation or, if appropriate, lactose breath test.

          -  Use of probiotics or topical and/or systemic antibiotic therapy during the last month.

          -  Systematic/frequent use of contact laxatives.

          -  Pregnant females or females of childbearing potential in the absence of effective
             contraceptive methods.

          -  Inability to conform to protocol.

          -  Treatment with any investigational drug within the previous 30 days.

          -  Recent history or suspicion of alcohol abuse or drug addiction.

          -  Presence of red or white flags at the Rome IV Psychosocial Alarm Questionnaire for
             Functional gastrointestinal Disorders.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Giovanni Barbara, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>AUO Sant'Orsola Malpighi Bologna (Gastroenterology)</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Patrucco</last_name>
    <phone>+39 02909231</phone>
    <email>laura.patrucco@sofarfarm.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Silvia Porta</last_name>
    <email>silvia.porta@sofarfarm.it</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. Bolognini</name>
      <address>
        <city>Seriate</city>
        <state>BG</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Fabio PAce</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico San Donato</name>
      <address>
        <city>San Donato Milanese</city>
        <state>MI</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Luca Pastorelli</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Gastroenterologia Universitaria Policlinico Giovanni XXIII</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Piero Portincasa</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda ULSS 1</name>
      <address>
        <city>Belluno</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Bastianello Germanà, Dr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria S. Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Giovanni Barbara, Professor</last_name>
      <phone>00390516364103</phone>
      <email>giovanni.barbara@unibo.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ospedale SS. Annunziata</name>
      <address>
        <city>Chieti</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Matteo Neri, professor</last_name>
      <phone>+390871-358092</phone>
      <email>mneri@unich.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico</name>
      <address>
        <city>Milano</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Guido Basilisco, doctor</last_name>
      <email>basilisc@policlinico.mi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico</name>
      <address>
        <city>Napoli</city>
        <zip>80100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rosario Cuomo, Professor</last_name>
      <email>rcuomo@unina.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Federico II</name>
      <address>
        <city>Napoli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Gerardo Nardone</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Francesca Galeazzi</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fondazione IRCCS Policlinico S. Matteo</name>
      <address>
        <city>Pavia</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Antonio Di Sabatino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>U.O. Gastroenterologia Universitaria</name>
      <address>
        <city>Pisa</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Santino Marchi, Professor</last_name>
      <email>s.marchi@int.med.unipi.it</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Biomedico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Michele Cicala, Professor</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. San Camillo-Forlanini</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rocco Cosentino</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>hospitall Sant'Andrea</name>
      <address>
        <city>Roma</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bruno Annibale</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Mearin F, Lacy BE, Chang L, Chey WD, Lembo AJ, Simren M, Spiller R. Bowel Disorders. Gastroenterology. 2016 Feb 18. pii: S0016-5085(16)00222-5. doi: 10.1053/j.gastro.2016.02.031. [Epub ahead of print]</citation>
    <PMID>27144627</PMID>
  </reference>
  <reference>
    <citation>Barbara G, Feinle-Bisset C, Ghoshal UC, Quigley EM, Santos J, Vanner S, Vergnolle N, Zoetendal EG. The Intestinal Microenvironment and Functional Gastrointestinal Disorders. Gastroenterology. 2016 Feb 18. pii: S0016-5085(16)00219-5. doi: 10.1053/j.gastro.2016.02.028. [Epub ahead of print]</citation>
    <PMID>27144620</PMID>
  </reference>
  <reference>
    <citation>Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology. 2009 May;136(6):1979-88. doi: 10.1053/j.gastro.2009.02.074. Epub 2009 May 7. Review.</citation>
    <PMID>19457422</PMID>
  </reference>
  <reference>
    <citation>Schoepfer AM, Schaffer T, Seibold-Schmid B, Müller S, Seibold F. Antibodies to flagellin indicate reactivity to bacterial antigens in IBS patients. Neurogastroenterol Motil. 2008 Oct;20(10):1110-8. doi: 10.1111/j.1365-2982.2008.01166.x. Epub 2008 Aug 6.</citation>
    <PMID>18694443</PMID>
  </reference>
  <reference>
    <citation>Langhorst J, Junge A, Rueffer A, Wehkamp J, Foell D, Michalsen A, Musial F, Dobos GJ. Elevated human beta-defensin-2 levels indicate an activation of the innate immune system in patients with irritable bowel syndrome. Am J Gastroenterol. 2009 Feb;104(2):404-10. doi: 10.1038/ajg.2008.86. Epub 2009 Jan 20.</citation>
    <PMID>19174795</PMID>
  </reference>
  <reference>
    <citation>Pimentel M, Morales W, Rezaie A, Marsh E, Lembo A, Mirocha J, Leffler DA, Marsh Z, Weitsman S, Chua KS, Barlow GM, Bortey E, Forbes W, Yu A, Chang C. Development and validation of a biomarker for diarrhea-predominant irritable bowel syndrome in human subjects. PLoS One. 2015 May 13;10(5):e0126438. doi: 10.1371/journal.pone.0126438. eCollection 2015.</citation>
    <PMID>25970536</PMID>
  </reference>
  <reference>
    <citation>Rajilić-Stojanović M, Biagi E, Heilig HG, Kajander K, Kekkonen RA, Tims S, de Vos WM. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 2011 Nov;141(5):1792-801. doi: 10.1053/j.gastro.2011.07.043. Epub 2011 Aug 5.</citation>
    <PMID>21820992</PMID>
  </reference>
  <reference>
    <citation>Jalanka-Tuovinen J, Salojärvi J, Salonen A, Immonen O, Garsed K, Kelly FM, Zaitoun A, Palva A, Spiller RC, de Vos WM. Faecal microbiota composition and host-microbe cross-talk following gastroenteritis and in postinfectious irritable bowel syndrome. Gut. 2014 Nov;63(11):1737-45. doi: 10.1136/gutjnl-2013-305994. Epub 2013 Dec 5.</citation>
    <PMID>24310267</PMID>
  </reference>
  <reference>
    <citation>Simrén M, Barbara G, Flint HJ, Spiegel BM, Spiller RC, Vanner S, Verdu EF, Whorwell PJ, Zoetendal EG; Rome Foundation Committee. Intestinal microbiota in functional bowel disorders: a Rome foundation report. Gut. 2013 Jan;62(1):159-76. doi: 10.1136/gutjnl-2012-302167. Epub 2012 Jun 22.</citation>
    <PMID>22730468</PMID>
  </reference>
  <reference>
    <citation>Moayyedi P, Ford AC, Talley NJ, Cremonini F, Foxx-Orenstein AE, Brandt LJ, Quigley EM. The efficacy of probiotics in the treatment of irritable bowel syndrome: a systematic review. Gut. 2010 Mar;59(3):325-32. doi: 10.1136/gut.2008.167270. Epub 2008 Dec 17. Review.</citation>
    <PMID>19091823</PMID>
  </reference>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 7, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>February 27, 2018</last_update_submitted>
  <last_update_submitted_qc>February 27, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">March 1, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Irritable Bowel Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

